ChemicalBook >> journal list >> Cell host & microbe >>article
Cell host & microbe

Cell host & microbe

IF: 18.7
Download PDF

Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19

Published:10 February 2021 DOI: 10.1016/j.chom.2020.12.016 PMID: 33388094
Qirui Guo, Yingchi Zhao, Junhong Li, Jiangning Liu, Xiuhong Yang, Xuefei Guo, Ming Kuang, Huawei Xia, Zeming Zhang, Lili Cao, Yujie Luo, Linlin Bao, Xiao Wang, Xuemei Wei, Wei Deng, Nan Wang, Luoying Chen, Jingxuan Chen, Hua Zhu, Ran Gao, Chuan Qin, Xiangxi Wang, Fuping You

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic poses an unprecedented public health crisis. Evidence suggests that SARS-CoV-2 infection causes dysregulation of the immune system. However, the unique signature of early immune responses remains elusive. We characterized the transcriptome of rhesus macaques and mice infected with SARS-CoV-2. Alarmin S100A8 was robustly induced in SARS-CoV-2-infected animal models as well as in COVID-19 patients. Paquinimod, a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice. Remarkably, Paquinimod treatment resulted in almost 100% survival in a lethal model of mouse coronavirus infection using the mouse hepatitis virus (MHV). A group of neutrophils that contributes to the uncontrolled pathological damage and onset of COVID-19 was dramatically induced by coronavirus infection. Paquinimod treatment could reduce these neutrophils and regain anti-viral responses, unveiling key roles of S100A8/A9 and aberrant neutrophils in the pathogenesis of COVID-19, highlighting new opportunities for therapeutic intervention.

Substances (3)

Materials Related products
Procduct Name CAS Molecular Formula Supplier Price
Paquinimod 248282-01-1 C21H22N2O3 96 suppliers $55.00-$2200.00
Paquinimod 248282-01-1 C21H22N2O3 96 suppliers $55.00-$2200.00

Similar articles

IF:4.7

Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19.

Infectious Diseases and Therapy Takahiro Takazono, Satoki Fujita,etc Published: 1 August 2024
IF:4.2

Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic

European journal of pharmacology Sobia Noreen, Irsah Maqbool,etc Published: 5 March 2021
IF:4.4

ACVR1 mediates renal tubular EMT in kidney fibrosis via AKT activation

Cellular signalling Tianli Yu, Zhangyu Mai,etc Published: 23 November 2024